What is HC Wainwright’s Forecast for BCRX Q4 Earnings?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities researchers at HC Wainwright lifted their Q4 2024 earnings estimates for BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, November 5th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn ($0.01) per share for the quarter, up from their previous forecast of ($0.03). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.49 EPS, FY2027 earnings at $0.91 EPS and FY2028 earnings at $1.31 EPS.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JMP Securities raised their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Finally, Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $7.73 on Thursday. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.88. The stock has a market cap of $1.60 billion, a PE ratio of -12.67 and a beta of 1.89. The firm’s 50 day moving average price is $7.80 and its two-hundred day moving average price is $6.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period last year, the company earned ($0.19) earnings per share. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. CWM LLC boosted its position in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares in the last quarter. Signaturefd LLC raised its holdings in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 5,599 shares during the period. Seven Eight Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $57,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,322 shares during the period. Finally, Natixis raised its holdings in shares of BioCryst Pharmaceuticals by 400.6% during the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 9,350 shares during the period. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.